超声心动图舒张功能障碍不能预测肝硬化患者经颈静脉肝内门体支架分流术后的生存
该研究纳入1999至2016年间在英国伯明翰肝病中心接受超声心动图及经颈静脉肝内门体支架分流术的117例肝硬化患者,由心脏病专家独立复核超声心动图指标。结果显示,干预前各项超声心动图指标均与术后30天及总体无移植生存无关,而终末期肝病模型(MELD)和Child-Pugh评分可显著预测生存。
要点
- 干预前超声心动图指标(含舒张功能障碍)均不能预测经颈静脉肝内门体支架分流术后的30天及总体无移植生存。
- MELD评分(P < 0.001)和Child-Pugh评分(P = 0.002)可显著预测30天及总体无移植生存。
- MELD ≥15提示死亡风险为三倍。
核心结论
- 肝硬化患者的心室功能障碍,尤其是舒张功能障碍,不能预测经颈静脉肝内门体支架分流术置入后的生存。
- MELD和Child-Pugh评分仍是生存的最佳预测指标。
- 需要进一步的前瞻性研究来明确经颈静脉肝内门体支架分流术置入前常规超声心动图的作用。
研究设计与样本
- 纳入1999至2016年间在英国伯明翰肝病中心接受超声心动图及经颈静脉肝内门体支架分流术置入的117例肝硬化患者。
- 所有超声心动图指标(包括左心室射血分数、早期最大心室充盈/晚期充盈速度比值、按英国超声心动图学会指南判定的舒张功能障碍)均由心脏病专家独立复核。
- 评估30天和总体无移植生存的预测因素。
主要发现
- 117例肝硬化患者中位年龄56岁,54%为酒精性病因,Child-Pugh B/C分别为71%和14.5%,MELD评分为12。
- 经颈静脉肝内门体支架分流术指征为腹水(n = 78)和静脉曲张出血(n = 39)。
- 中位随访663天(IQR 385-2368)期间,30天和总体无移植生存率分别为90%(n = 105)和31%(n = 36)。
- 6%(n = 7)的患者术前有缺血性心脏病史,34%(n = 40)有1个或以上心血管疾病危险因素;50%(n = 59)超声心动图异常,33%(n = 39)存在1-3级舒张功能障碍。
- 单因素分析显示,干预前各项超声心动图指标均与经颈静脉肝内门体支架分流术后的30天或总体无移植生存无关。
关键数值与推荐
- MELD评分(P < 0.001)和Child-Pugh评分(P = 0.002)可显著预测30天及总体无移植生存。
- MELD ≥15提示死亡风险为三倍。
临床怎么用
- MELD和Child-Pugh评分仍是经颈静脉肝内门体支架分流术置入后生存的最佳预测指标。
- 作者认为,需要进一步的前瞻性研究来明确经颈静脉肝内门体支架分流术置入前常规超声心动图的作用。
局限性
- 需要进一步的前瞻性研究来明确经颈静脉肝内门体支架分流术置入前常规超声心动图的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac dysfunction is frequently observed in patients with cirrhosis. There remains a paucity of data from routine clinical practice regarding the role of echocardiography in the pre-assessment of transjugular intrahepatic portosystemic stent-shunt. AIM: Our study aimed to investigate if echocardiography parameters predict outcomes after transjugular intrahepatic portosystemic stent-shunt insertion in cirrhosis. METHODS: Patients who underwent echocardiography and transjugular intrahepatic portosystemic stent-shunt insertion at the liver unit (Birmingham, UK) between 1999 and 2016 were included. All echocardiography measures (including left ventricle ejection fraction; early maximal ventricular filling/late filling velocity ratio, diastolic dysfunction as per British Society of Echocardiography guidelines) were independently reviewed by a cardiologist. Predictors of 30-day and overall transplant free-survival were assessed. RESULTS: One Hundred and Seventeen patients with cirrhosis (median age 56 years; 54% alcohol; Child-Pugh B/C 71/14.5%; Model For End-Stage Liver Disease 12) underwent transjugular intrahepatic portosystemic stent-shunt for ascites (n = 78) and variceal haemorrhage (n = 39). Thirty-day and overall transplant-free survival was 90% (n = 105) and 31% (n = 36), respectively, over a median 663 (IQR 385-2368) days follow-up. Model for End-Stage Liver Disease (P < 0.001) and Child-Pugh Score (P = 0.002) significantly predicted 30-day and overall transplant-free survival. Model for End-Stage Liver Disease ≥15 implied three-fold risk of death. Six per cent (n = 7) of patients pre-transjugular intrahepatic portosystemic stent-shunt had a history of ischaemic heart disease and 34% (n = 40) had 1 or more cardiovascular disease risk factors. Fifty per cent (n = 59) had an abnormal echocardiogram and 33% (n = 39) had grade 1-3 diastolic dysfunction. On univariate analysis none of the echocardiography measures pre-intervention were related to 30-day or overall transplant-free survival post-transjugular intrahepatic portosystemic stent-shunt. CONCLUSIONS: Ventricular, in particular diastolic dysfunction in patients with cirrhosis does not predict survival after transjugular intrahepatic portosystemic stent-shunt insertion. Model for End-Stage Liver Disease and Child-Pugh scores remain the best predictors of survival. Further prospective study is required to clarify the role of routine echocardiography prior to transjugular intrahepatic portosystemic stent-shunt insertion.
引用
- Armstrong MJ, Gohar F, Dhaliwal A, et al. Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 30773660. doi:10.1111/apt.15164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。